Pai et al., 2019 - Google Patents
Clonal deletion of tumor-specific T cells by interferon-γ confers therapeutic resistance to combination immune checkpoint blockadePai et al., 2019
View HTML- Document ID
- 11742810157361271368
- Author
- Pai C
- Huang J
- Lu X
- Simons D
- Park C
- Chang A
- Tamaki W
- Liu E
- Roybal K
- Seagal J
- Chen M
- Hagihara K
- Wei X
- DuPage M
- Kwek S
- Oh D
- Daud A
- Tsai K
- Wu C
- Zhang L
- Fasso M
- Sachidanandam R
- Jayaprakash A
- Lin I
- Casbon A
- Kinsbury G
- Fong L
- Publication year
- Publication venue
- Immunity
External Links
Snippet
Resistance to checkpoint-blockade treatments is a challenge in the clinic. We found that although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of established tumors, this combination compromised anti-tumor immunity in the low tumor …
- 210000001744 T-Lymphocytes 0 title abstract description 144
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pai et al. | Clonal deletion of tumor-specific T cells by interferon-γ confers therapeutic resistance to combination immune checkpoint blockade | |
| Chow et al. | Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy | |
| Meyer et al. | Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance | |
| Crosby et al. | Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors | |
| Tacconi et al. | CD169+ lymph node macrophages have protective functions in mouse breast cancer metastasis | |
| Ngo et al. | Antibody therapy targeting CD47 and CD271 effectively suppresses melanoma metastasis in patient-derived xenografts | |
| Cable et al. | Frontiers in cancer immunotherapy—a symposium report | |
| Kamali et al. | Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands | |
| Castro et al. | Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule | |
| EP4069284A1 (en) | Tumor cell vaccines | |
| US10753938B2 (en) | Beta-catenin inhibitors in cancer immunotherapy | |
| Wong et al. | Evolving adoptive cellular therapies in urological malignancies | |
| Lanier et al. | Immunotherapy approaches for hematological cancers | |
| US20210023134A1 (en) | Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1bb agonist | |
| Schaettler et al. | TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma | |
| Deng et al. | Immunotherapy for ovarian Cancer: disappointing or promising? | |
| Oli et al. | Tumour immunotherapy and applications of immunological products: A review of literature | |
| Nikoo et al. | Potential of chimeric antigen receptor (CAR)‐redirected immune cells in breast cancer therapies: Recent advances | |
| WO2021168375A1 (en) | Chimeric antigen receptor t cell therapy | |
| Lo Presti et al. | Use of cord blood derived T-cells in cancer immunotherapy: milestones achieved and future perspectives | |
| Osorio et al. | Intratumoral Fc-optimized agonistic CD40 antibody induces tumor rejection and systemic antitumor immunity in patients with metastatic cancer | |
| WO2022094391A2 (en) | Breast cancer tumor cell vaccines | |
| Gupta et al. | Immunotherapy in OSCC: Current trend and challenges | |
| Mistarz et al. | Recruitment of intratumoral CD103+ dendritic cells by a CXCR4 antagonist-armed virotherapy enhances antitumor immunity | |
| CA2874065A1 (en) | Methods and compositions for treating breast cancer with dendritic cell vaccines |